, positively stain (1, 2, 7-10) and express genes (8, 10) for intact gonadotropins and/or their free subunits. Moreover, they can present functioning receptors for gonadotropinreleasing hormone (GnRH), because release of gonado¬ tropins (3, 7) , increased inositol phospholipid turnover (11) and intracellular free calcium mobilization (12) have been reported to occur in vitro in these tumors following GnRH administration. The hypothesis of their origin from gonadotroph cells has been suggested (13 (14) .
Up to now, the administration of various GnRH agonists (buserelin, goserelin, leuprolide, tryptorelin) was reported to cause tumor mass shrinkage in only a minority of patients with NFPA or true gonadotropinomas, with variable changes of circulating LH, FSH and -subunit (aSU) levels (15) (16) (17) (18) (19) (20) (21) .
In this work, we report on the effects of long-term Circulating levels of qSU were measured by previously described methods (23) . The assay sensitivity was 0. ¬ .3 µg/l and the intra-and interassay coefficients of variation were below 7.8% and 9.6%, respectively. Serum testosterone and E2 levels were measured in unextracted serum by specific direct RIA methods (Coat-A-Count, Diagnostic Products Corporation, USA, and Biodata SpA, Italy, respectively). The intra-and interassay coefficients of variation were 6.3% and 10.4% for testosterone and 7.5% and 9.0% for E2, respectively.
The lower limit of sensitivity of the assays was 0.1 nmol/1 for both hormones.
Normal basal values were considered as follows: in postmenopausal women, LH 20-100 U/l, U/l, E2 < 0.1 nmol/1, qSU 0. 4 and showed only a minimal increase in patient no. 5 throughout the whole period of treatment (Fig. 2) gonadotropins and/or their free subunits (1, 2, 7-10).
The administration of GnRH into culture medium had showed an intracellular free calcium rise in the two examined adenomas, a feature probably correlated to the presence of functioning GnRH receptors in these tumors, as suggested already in previous reports (11, 12 (16, (18) (19) (20) (21) , while others showed reduction (17, 19, 21) or no changes (15, 21) of hormonal values.
The doses of nafarelin administered intranasally to our patients were comparable or even higher than those able to induce a reduction of sex hormone levels in normal subjects (23) and in patients with hormonedependent conditions, such as endometriosis and precocious puberty (24, 25) . (4, 9) . Moreover, a rise of gonado¬ tropin levels during GnRH analog therapy was a common finding in most patients with gonadotropinomas examined so far (16, (18) (19) (20) .
Regarding (26, 27) . For (iii) stimulation rather than inhibition of gonado¬ tropin levels during GnRH analog therapy might predict enlargement of tumor size and suggest that therapy be discontinued.
